Clinical Trial Update: Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines [Phase 2, Phase 3]

View source ↗

Summary

A trial evaluating safety and immunogenicity of 2 doses versus 1 dose of acellular pertussis vaccines containing genetically-detoxified pertussis toxin in young…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pertussis

Drugs mentioned

• Acellular pertussis vaccines containing genetically-detoxified pertussis toxin

Snippet

Sponsor: University Hospital, Geneva | Conditions: Pertussis, Vaccine-Preventable Diseases | Phase 2, Phase 3 | Status: UNKNOWN